Skip to main content

As of June 20, 2025

INDICATIONS

EYLEA HD® (aflibercept) Injection 8 mg is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

EYLEA® (aflibercept) Injection 2 mg is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

IMPORTANT SAFETY INFORMATION FOR EYLEA HD AND EYLEA

CONTRAINDICATIONS

  • EYLEA HD and EYLEA are contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA HD or EYLEA.

Please see additional Important Safety Information below.

EYLEA HD Coverage and Access

100% of eligible patients with Medicare Fee-for-Service (FFS) have first-line access to EYLEA HD with no prior authorization or step edit required1

* Individual plan policies may vary, and the information presented herein does not replace a benefit verification. All formulary data and other access criteria are provided by Managed Markets Insight & Technology, LLC database as of January 2025 and EYLEA HD imputed sales as of November 2024.
† Prior authorization may still be required.

Bevacizumab Shortage

Due to a recent market event, Pine Pharmaceuticals, one of the largest producers of repackaged bevacizumab, communicated that it is exiting the market for repackaging bevacizumab in pre-filled syringes, and there will likely be a shortage of available product.

  • For your clinically appropriate patients, consider transitioning to EYLEA HD to prevent disruption in treatment. Reach out to your RBM for a Sample Letter of Medical Exception.

Your RBMs can provide support to help facilitate this process and will provide resources regarding EYLEA HD. It is recommended that your prior authorization includes the request to bypass the bevacizumab step requirement due to the shortage and/or include a Letter of Medical Exception with the prior authorization request.

Medicare in Focus

Our Medicare in Focus initiative provides patients with information and education on the differences between Original Medicare and Medicare Advantage to support their selection of the most appropriate coverage based on their needs.

You can visit and direct your patients to medicareinfocus.com to access helpful resources, such as informational videos and a guide to frequently asked questions.

EYLEA HD Payer Coverage

Coverage News!
UnitedHealthcare Medicare Advantage
• DME and DR: First-line access, no step edit*
• Wet AMD: Single agent step through 3 consecutive monthly bevacizumab injections*
Medicare Fee-For-Service (FFS)
• 100% of eligible patients with Medicare FFS have first-line access to EYLEA HD with no prior authorization or step edit required1

For an up-to-date payer coverage report for national and regional payers, click here

Please be sure to clear your browser cache and history to view the latest payer coverage report via the link above.

EYLEA HD is covered on the VA national formulary for Wet AMD, DME, and DR with no step edits or restrictions.† EYLEA HD is available for first-line use.

Contact your RBM to learn more

EYLEA HD and EYLEA Payer Policy Portal

For more information about payer coverage for EYLEA HD and EYLEA, contact your RBM or click here to visit the EYLEA HD and EYLEA Payer Policy Portal to access certain payer policy information.

  • Find health plan coverage for EYLEA HD and EYLEA for each state through different channels and indications
  • Check the coverage status for various health plans, including step edits and prior authorization requirements

This information is provided for informational purposes only, is subject to change, and should not be construed as legal or medical advice. This information may not apply to all patients or to all health plans and providers should exercise independent judgment when submitting claims.

* Prior authorization may still be required.
† Based on formulary data from June 2025, EYLEA HD is on the VA national formulary with no restrictions or criteria for use listed: https://www.va.gov/formularyadvisor/drugs/4031221-AFLIBERCEPT-INJ-SOLN
* Prior authorization may still be required.
† Based on formulary data from June 2025, EYLEA HD is on the VA national formulary with no restrictions or criteria for use listed: https://www.va.gov/formularyadvisor/drugs/
4031221-AFLIBERCEPT-INJ-SOLN

Reimbursement Information for EYLEA HD3

Vial kit with injection components

  • One EYLEA HD 8 mg (0.07 mL of a 114.3 mg/mL solution), single-dose glass vial
  • One 18-gauge x 11/2-inch, 5-micron filter needle for withdrawal of the vial contents
  • One 30-gauge x 1/2-inch injection needle for intravitreal injection
  • One 1-mL syringe for administration
  • One Prescribing Information

NDC

  • 6175505001
  • 61755005001

Note: The product’s NDC has been “zero-filled” to ensure creation of an 11-digit code that meets general billing standards. The zero-fill location is indicated in bold.

Ask your RBM about the EYLEA HD Comprehensive Product Acquisition Brochure, which includes more information on how you can acquire EYLEA HD for your practice.

Permanent J-code for EYLEA HD4

  • J0177, Injection, aflibercept hd, 1 mg, is effective for dates of service on or after April 1, 2024
  • With the permanent J-code, billing units for EYLEA HD must be reported based on the unit value for the assigned permanent code. EYLEA HD is reported with “8” units of J0177 per treatment

Modifiers required on Medicare FFS claims for EYLEA HD and EYLEA

As of October 1, 2023, claims for drugs from single-dose containers that do not use the required modifiers (JZ and JW) may be returned.5

Reminder: HCPs are required to report the JZ modifier when submitting Medicare FFS claims from all outpatient settings. The JZ modifier is used to attest that no amount of drug was discarded and eligible for payment and that no JW modifier amount is reported (a JW modifier, required since July 1, 2023, is used when indicating that the discarded drug was not administered to a patient). Like the JW modifier, the JZ modifier should only be used for claims that bill for single-dose container drugs as approved by the FDA.

Click here to learn more.

Payment Terms, WAC Discount, and ASP Information for EYLEA HD

Payment terms for EYLEA HD: Effective August 18, 2023

Physician payment terms will be 120 days, subject to distributor qualification.*†

Discount for EYLEA HD: Effective April 1, 2025

The wholesale acquisition cost (WAC) discount is 8.75% on EYLEA HD for community-based physicians in solo or group practices who are treating patients on an outpatient basis (if ordered through authorized distributors).‡

* These payment terms are subject to change. Regeneron worked with its authorized distributors of record to apply these terms for EYLEA HD.
† Subject to distributor qualification. Please verify with your distributor the timing and specific dating terms that apply to your office.
‡ This discount applies only to eligible purchasers ordering from authorized distributors. See EYLEAHDhcp.us for additional discount terms. The EYLEA HD WAC discount is subject to change.
§ WAC serves as the list price for EYLEA HD. It does not necessarily reflect the end price paid by purchasers.
∥ Rebates are subject to additional terms and conditions, including eligibility criteria. Please contact your Regeneron Ophthalmology Account Director for additional information.
  The discount and rebates described herein are intended to constitute a discount as such term is defined in 42 U.S.C. § 1320a-7b(b)(3) and 42 C.F.R. § 1001.952(h). As such, participating physicians have an obligation to comply with all retention, disclosure, and reporting requirements regarding the value of any discounts or rebates paid or received, including those described herein, pursuant to 42 U.S.C. § 1320a-7b(b)(3) and 42 C.F.R. § 1001.952(h) and all other applicable federal and state laws and regulations.
  The EYLEA HD WAC discount is an independent and non-contingent offering specific to EYLEA HD.

Participating GPOs and Authorized Specialty Distributors

GPOs:
 Acuity; AllyRetina; IPN; Onmark; Matrix

Specialty Distributors:
Besse Medical; BioCareSD; CuraScript SD Specialty Distribution; McKesson Specialty Health; McKesson Plasma & Biologics for Hospitals; Metro Medical (A Cardinal Health Company); and Cardinal Health Specialty Pharmaceutical Distribution for Hospitals

Contact one of our authorized distributors and receive EYLEA HD on the next business day. Orders received prior to 7 PM Eastern Time Monday–Thursday are typically processed on the same day and scheduled for delivery the next business day. Orders received on Friday will typically be delivered the following Monday.

Regeneron does not recommend the use of a particular authorized distributor or GPO. 

GPO and specialty distributor added as of October 1, 2024.

ASP for EYLEA HD

Effective as of April 1, 2025, the ASP for EYLEA HD in Q2 2025 is $2,423.97.

Access News Roundup

Access-related news affecting the retina care landscape

A CMS claims system issue is causing denials for Medicare and Medicare Advantage claims related to treating Wet AMD and geographic atrophy (GA) when both treatments are given within 25-28 days. The first treatment is typically reimbursed, but the second drug and injection code are being denied.

ASRS and AAO are working with CMS to remove the edit, and retina practices are encouraged to appeal, arguing that Wet AMD and GA are distinct diseases treated with different drugs, all following FDA guidelines.6

Medicare’s WPS MAC will reprocess denied claims for anti-VEGF and Syfovre injections administered close together, reimbursing for the previously denied drug. This follows CMS’s policy limiting anti-VEGF administration to once every 28 days. However, WPS clarified that Syfovre (HCPCS code J2781) is no longer subject to this limitation, allowing both types of drugs to be given within FDA-approved dosing intervals. Efforts are ongoing to see if other complement inhibitors will also be excluded from the edit and how other MACs will respond.7

  • Unlike traditional Medicare, nearly all Medicare Advantage enrollees (99%) must obtain prior authorization for certain higher-cost treatments and services8

    • In 2023, Medicare Advantage plans made nearly 50 million prior authorization determinations—up from 42 million in 2022
    • 3.2 million of these requests were partially or fully denied, and 11.7% of the requests were appealed
    • However, ~82% of appeals resulted in overturning the initial prior authorization denial

  • Despite coverage complexities, most beneficiaries didn’t compare plan options during open enrollment9

    • 69% of Medicare beneficiaries overall and 65% of Medicare Advantage enrollees did not explore other coverage options for 2022, even though plan changes could impact access to care
    • Certain subgroups were even less likely to compare coverage: 82% of those aged 85 years and older, 79% of Hispanic individuals, and 77% of those making <$10,000 annually compared coverage during open enrollment

Reform for Medicare Advantage Policies

CMS released its 2025 Medicare Advantage and Part D plan year final rule, which includes a requirement that Medicare Advantage plans incorporate health equity experts into their utilization management committees and conduct annual health equity assessments of prior authorization policies.10

Educational Opportunities

Practice Administrator Educational Programs

There are several speaker programs available to educate practice administrators and staff on specific topics related to EYLEA HD and EYLEA. 

Topics include:

  • Access and reimbursement information
  • Understanding market access dynamics within your account
  • Helpful tips when reviewing payer contracts and documentation
  • Processes for benefit verification, prior authorization, medical exceptions, and appeals

Click here to connect with your Regeneron RBM for more information about these speaker programs.

Helpful Documentation Considerations Resource

The Helpful Documentation Considerations guide is available for office use. It provides tips to help ensure proper documentation and a checklist to confirm that the necessary EYLEA HD clinical information is included in all appropriate paperwork to be submitted to payers. It is distributed by RBMs to help physicians facilitate payer coverage and reduce prior authorization denials.

EYLEA4U Information

The EYLEA4U Patient Support Program can provide you with benefit verification support for your patients. All programs within EYLEA4U are available for both EYLEA HD and EYLEA. EYLEA4U forms include both EYLEA and EYLEA HD, which can help streamline the process of enrolling patients who require treatment with EYLEA HD, including those transitioning from EYLEA to EYLEA HD in the EYLEA4U Commercial Copay Card Program or Patient Assistance Program (PAP).

Please note: To receive payments for EYLEA HD through the EYLEA4U Commercial Copay Program, you must complete (one-time only) an EYLEA4U Healthcare Provider Representation Form.

 

If you haven’t completed this form, please contact your RBM or call EYLEA4U at 1-855-EYLEA4U (1-855-395-3248), Option 4, Monday–Friday, 9 am–8 pm Eastern Time to receive a form today.  

Click here for the EYLEA4U Provider Portal.

EYLEA4U Online Via Tablet-Based Technology*

Tablet-based technology that interfaces with electronic medical record, practice management, and inventory management system technology and can connect patients to all EYLEA4U support services.

  • Electronic signature capture for tablet enrollment† 
  • Electronic submissions in real time 
  • Electronic enrollment solutions can offer benefit verification accuracy

Contact your Reimbursement Business Manager if you are interested in utilizing the tablet.

* Requires the use of a tablet provided by Regeneron’s third-party technology source and a license paid for by the HCP office.
† For tablet only; portal enrollment requires patient signature to be filed.

Coming soon: The EYLEA4U ePortal is moving to a new platform! Over the next few weeks, you will receive more detailed information, including instructions on how to register your users for access to the new ePortal.

Navigating Payer Challenges (NPC)

The NPC resource contains information for HCPs and office administrators that may facilitate how to access, submit claims, and seek reimbursement to support their patients’ access to EYLEA.
You can also visit NavigatingPayerChallenges.com to:
  • Download updated state, US territory, or ancillary NPC flash cards
  • Review Payer Reimbursement Time Frames and Penalties that plans must adhere to for reimbursing for services rendered by health care providers within the 50 states, US territories, ERISA, and Medicare Advantage
  • Find information about the status of state and federal Gold Card Act legislation, which is legislation that allows prequalified providers with a specific prior approval rate to bypass the prior authorization process for certain procedures over a defined period11
We recommend bookmarking the website for your convenience. Updates to the site will be made on a regular basis.

Ask your RBM for a Payer Business Review for your specific location.

Your RBM can provide a local review of your payer landscape and answer questions related to coverage of EYLEA HD in your specific location. Your RBM can also provide state-specific information and an overview resource of several laws and regulations that may apply to patient insurance and payer issues.

CMS Policy Pulse12,13

Responding to criticisms of the current prior authorization (PA) process, CMS has issued a new rule requiring health plans to send PA decisions within three days for urgent requests and within seven days for standard requests.

The new rule, effective in 2026, also requires payers to provide an explanation for every denial of a PA and publicly report their PA metrics.

By 2027, payers will have to implement a PA application programming interface (API) to improve the electronic exchange of health information and automation of the PA process. 

CMS estimates the new rule will save approximately $15 billion over 10 years by reducing the administrative burden of PAs and improving patient outcomes.

Stay up-to-date with the latest information on audits from CMS

Current MAC Medical Review List

MAC EYLEA J0178 Medical Review Links
CGS J15 Part B TPE review Link
Palmetto JJ Part B TPE review Link
Palmetto JM Part B TPE review Link

As of June 2025.

Product Support

Click here for a list of authorized specialty distributors and specialty pharmacy providers for EYLEA HD and EYLEA.

Regeneron does not recommend the use of any particular authorized distributor or specialty pharmacy.

Resources

Your dedicated RBM can provide support to help your eligible patients access EYLEA HD and EYLEA. They provide support in areas including access and reimbursement, financial assistance, and health plan policy, and can provide you with various educational tools and resources.

Contact your RBM to learn more about the latest tools and resources available for EYLEA HD and EYLEA:

  • EYLEA HD and EYLEA Payer Policy Portal
  • Enables your practice administrators and office staff to access certain payer policy information for EYLEA HD and EYLEA
  • Payer Access Business Review
  • Provides high-level national, state, and individualized office data to analyze EYLEA HD coverage trends and aggregate data from EYLEA4U, our patient support program, for your overall organization and individual offices
  • FormTrak Coverage Flash Cards
  • Provides coverage status for EYLEA HD and EYLEA by health plan, channel, and location
  • Know Your Medical and Pharmacy Directors Flash Card
  • Helps your practice understand the importance of having a rapport with medical and pharmacy directors at health plans and how advocating can lead to successful appeals and influence medical policy
  • Helpful Documentation Considerations Guide

  • Provides your office staff with tips and a checklist to ensure proper documentation for EYLEA HD coverage

  • Medicare In Focus
  • Provides patients with information and education on the differences between Original Medicare and Medicare Advantage to support their selection of the most appropriate coverage based on their needs

Visit the Resource Center at the EYLEA HD HCP website to download information about EYLEA HD, including:

  • Prior Authorization Checklist Flash Card
  • Billing and Coding Brochure
  • Appeals Letter Overview Brochure
  • EYLEA4U Annotated Enrollment Form Brochure
  • EYLEA4U Overview Brochure for HCPs

The EYLEA4U Practice Administrator Speaker Program is designed to educate practice administrators and their staff on specific topics related to EYLEA HD and EYLEA. Contact your RBM for the Practice Administrator Speaker Program (RAP) Overview Flash Card to see the wide variety of topics covered through this program.

IMPORTANT SAFETY INFORMATION FOR EYLEA HD AND EYLEA (cont’d)

WARNINGS AND PRECAUTIONS

  • Intravitreal injections, including those with aflibercept, have been associated with endophthalmitis and retinal detachments and, more rarely, retinal vasculitis with or without occlusion. Proper aseptic injection technique must always be used when administering EYLEA HD or EYLEA. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
  • Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA HD and EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
  • There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA HD and EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
    • EYLEA HD: The incidence of reported thromboembolic events in the wet AMD study (PULSAR) from baseline through week 48 was 0.4% (3 out of 673) in the combined group of patients treated with EYLEA HD compared with 1.5% (5 out of 336) in patients treated with EYLEA 2 mg. The incidence in the DME study (PHOTON) from baseline to week 48 was 3.1% (15 out of 491) in the combined group of patients treated with EYLEA HD compared with 3.6% (6 out of 167) in patients treated with EYLEA 2 mg.
    • EYLEA: The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the EYLEA group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.

ADVERSE REACTIONS

  • EYLEA HD:
    • The most common adverse reactions (≥3%) reported in patients receiving EYLEA HD were cataract, conjunctival hemorrhage, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, vision blurred, vitreous floaters, vitreous detachment, corneal epithelium defect, and retinal hemorrhage.
  • EYLEA:
    • Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.
    • The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
  • Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA HD or EYLEA and the associated eye examinations. Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Please see full Prescribing Information for EYLEA HD and EYLEA.

AMD = age-related macular degeneration; AAO = American Academy of Ophthalmology; ASP = average sales price; ASRS = American Society of Retina Specialists; BCBS = Blue Cross Blue Shield; CMS = Centers for Medicare & Medicaid Services; DME = diabetic macular edema; DR = diabetic retinopathy; ERISA = Employee Retirement Income Security Act; HCP = health care provider; HCPCS = Healthcare Common Procedure Coding System; GPO = group purchasing organization; MAC = Medicare Administrative Contractor; NDC = National Drug Code; RBM = Reimbursement Business Manager; VA = Veterans Affairs; WPS = Wisconsin Physician Services.

References: 1. Centers for Medicare & Medicaid Services. Medicare Benefit Policy Manual, Chapter 15: Covered medical and other health services. Revised October 4, 2024. Accessed October 25, 2024. https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/bp102c15.pdf 2. Data on file. Regeneron Pharmaceuticals, Inc. 3. EYLEA HD full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. October 2024. 4. Centers for Medicare & Medicaid Services. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) application summaries and coding recommendations: fourth quarter, 2023 HCPCS coding cycle. Accessed October 1, 2024. https://www.cms.gov/files/document/2023-hcpcs-application-summary-quarter-4-2023-drugs-and-biologicals-updated-04/25/2024.pdf 5. Medicare program: discarded drugs and biologicals—JW modifier and JZ modifier policy frequently asked questions. Accessed October 1, 2024. https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf 6. American Society of Retina Specialists. ASRS seeks to remove CMS edit for billing Wet and Dry AMD treatments in the same month. February 18, 2025. Accessed March 3, 2025. https://www.asrs.org/advocacy/updates/10407/asrs-seeks-to-remove-cms-edit-for-billing-wet-and-dry-amd-treatments-in-the-same-month 7. American Society of Retina Specialists. WPS will reprocess denied claims for dual administrations of anti-VEGF and Synfovre. March 4, 2025. Accessed March 11, 2025. https://www.asrs.org/advocacy/updates/10411/wps-will-reprocess-denied-claims-for-dual-administrations-of-anti-vegf-and-syfovre 8. Biniek JF, Sroczynski N, Freed M, Neuman T. Medicare Advantage insurers made nearly 50 million prior authorization determinations in 2023. Published January 28, 2025. Accessed March 3, 2025. https://www.kff.org/medicare/issue-brief/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2023/ 9. Ochieng N, Cubanski J, Freed M, Neuman T. Nearly 7 in 10 Medicare beneficiaries did not compare plans during Medicare’s open enrollment period. KFF. Published September 26, 2024. Accessed September 27, 2024. https://www.kff.org/medicare/issue-brief/nearly-7-in-10-medicare-beneficiaries-did-not-compare-plans-during-medicares-open-enrollment-period/ 10. Centers for Medicare & Medicaid Services. Contract year 2025 Medicare Advantage and Part D final rule (CMS-4205-F). Accessed September 27, 2024. https://www.cms.gov/newsroom/fact-sheets/contract-year-2025-medicare-advantage-and-part-d-final-rule-cms-4205-f 11. Robeznieks A. New physician “gold card” law will cut prior authorization delays. American Medical Association. Accessed October 29, 2024. https://www.ama-assn.org/practice-management/prior-authorization/new-physician-gold-card-law-will-cut-prior-authorization 12. CMS finalizes rule to expand access to health information and improve the prior authorization process. News release. Centers for Medicare & Medicaid Services. Accessed October 1, 2024. https://www.cms.gov/newsroom/press-releases/cms-finalizes-rule-expand-access-health-information-and-improve-prior-authorization-process 13. Tong N. CMS finalizes rule setting prior authorization deadlines for payers. Accessed October 1, 2024. https://www.fiercehealthcare.com/payers/cms-introduce-prior-authorization-deadlines-payers

EYLEA HD, EYLEA, and EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.
All other trademarks are property of their respective owners.

IMPORTANT SAFETY INFORMATION FOR EYLEA HD AND EYLEA +
CONTRAINDICATIONS
• EYLEA HD and EYLEA are contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA HD or EYLEA.